BMS' Bid For Opdivo In First-Line HCC Stymied

 
• By Joseph Haas
  
Digital illustration of lung cancer cells in color background - Illustration
Opdivo is approved for second-line HCC therapy

More from Immuno-oncology

More from Anticancer